161 related articles for article (PubMed ID: 20158477)
81. Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases.
Chakraborty S; Inukai T; Fang L; Golkowski M; Maly DJ
ACS Chem Biol; 2019 Jun; 14(6):1249-1259. PubMed ID: 31038916
[TBL] [Abstract][Full Text] [Related]
82. Src inhibitors: genomics to therapeutics.
Sawyer T; Boyce B; Dalgarno D; Iuliucci J
Expert Opin Investig Drugs; 2001 Jul; 10(7):1327-44. PubMed ID: 11772255
[TBL] [Abstract][Full Text] [Related]
83. SRC as a therapeutic target in breast cancer.
Morgan L; Nicholson RI; Hiscox S
Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):273-8. PubMed ID: 19075780
[TBL] [Abstract][Full Text] [Related]
84. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen T; George JA; Taylor CC
Anticancer Drugs; 2006 Feb; 17(2):123-31. PubMed ID: 16428929
[TBL] [Abstract][Full Text] [Related]
85. Recent advances in inhibitors of C-terminal SRC kinase.
P O'Malley D
Future Med Chem; 2020 Aug; 12(16):1447-1449. PubMed ID: 32638626
[No Abstract] [Full Text] [Related]
86. Src-family tyrosine kinases as therapeutic targets in advanced cancer.
Gelman IH
Front Biosci (Elite Ed); 2011 Jun; 3(3):801-7. PubMed ID: 21622091
[TBL] [Abstract][Full Text] [Related]
87. Cytoplasmic signalling domains: the next generation.
Bork P; Schultz J; Ponting CP
Trends Biochem Sci; 1997 Aug; 22(8):296-8. PubMed ID: 9270302
[TBL] [Abstract][Full Text] [Related]
88. Src family kinases in chronic kidney disease.
Wang J; Zhuang S
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F721-F728. PubMed ID: 28615246
[TBL] [Abstract][Full Text] [Related]
89. Src kinase and pancreatic cancer.
Hilbig A
Recent Results Cancer Res; 2008; 177():179-85. PubMed ID: 18084959
[TBL] [Abstract][Full Text] [Related]
90. Potent and selective inhibition of SH3 domains with dirhodium metalloinhibitors.
Vohidov F; Knudsen SE; Leonard PG; Ohata J; Wheadon MJ; Popp BV; Ladbury JE; Ball ZT
Chem Sci; 2015 Aug; 6(8):4778-4783. PubMed ID: 29142714
[TBL] [Abstract][Full Text] [Related]
91. Chemoproteomic Method for Profiling Inhibitor-Bound Kinase Complexes.
Fang L; Chakraborty S; Dieter EM; Potter ZE; Lombard CK; Maly DJ
J Am Chem Soc; 2019 Jul; 141(30):11912-11922. PubMed ID: 31274292
[TBL] [Abstract][Full Text] [Related]
92. Seeking a better understanding of the non-receptor tyrosine kinase, SRMS.
Goel RK; Kim N; Lukong KE
Heliyon; 2023 Jun; 9(6):e16421. PubMed ID: 37251450
[TBL] [Abstract][Full Text] [Related]
93. Regulation of SRC family kinases in human cancers.
Sen B; Johnson FM
J Signal Transduct; 2011; 2011():865819. PubMed ID: 21776389
[TBL] [Abstract][Full Text] [Related]
94. Species-specific interactions of Src family tyrosine kinases regulate Chlamydia intracellular growth and trafficking.
Elwell CA; Kierbel A; Engel JN
mBio; 2011; 2(3):e00082-11. PubMed ID: 21586644
[TBL] [Abstract][Full Text] [Related]
95. BiTtEn by Src inhibitors.
Rousselot P
Blood; 2021 Feb; 137(7):867-868. PubMed ID: 33599758
[No Abstract] [Full Text] [Related]
96. Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis).
Sgalla G; Richeldi L
Am J Respir Crit Care Med; 2022 Dec; 206(12):1439-1440. PubMed ID: 36018567
[No Abstract] [Full Text] [Related]
97. Anticancer drugs: SRC hits the mark.
Burgess DJ
Nat Rev Drug Discov; 2011 May; 10(5):338-9. PubMed ID: 21532559
[No Abstract] [Full Text] [Related]
98. The Relevance of the SH2 Domain for c-Src Functionality in Triple-Negative Breast Cancer Cells.
Mayoral-Varo V; Sánchez-Bailón MP; Calcabrini A; García-Hernández M; Frezza V; Martín ME; González VM; Martín-Pérez J
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530373
[TBL] [Abstract][Full Text] [Related]
99. Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer.
Tzou YM; Bailey SK; Yuan K; Shin R; Zhang W; Chen Y; Singh RK; Shevde LA; Krishna NR
Bioorg Med Chem Lett; 2016 Feb; 26(4):1237-44. PubMed ID: 26803204
[TBL] [Abstract][Full Text] [Related]
100. Regions outside of conserved PxxPxR motifs drive the high affinity interaction of GRB2 with SH3 domain ligands.
Bartelt RR; Light J; Vacaflores A; Butcher A; Pandian M; Nash P; Houtman JC
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2560-9. PubMed ID: 26079855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
